Today: 30 April 2026
Browse Category

NASDAQ:ASBP 11 November 2025 - 15 December 2025

Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching

Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching

Aspire Biopharma shares fell about 8% to $0.095 on December 15, 2025, as the company’s stock transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market. Aspire faces Nasdaq deadlines to regain compliance with minimum bid price and equity rules by early 2026. The company is also advancing an FDA regulatory milestone for its sublingual aspirin program.
15 December 2025
·
Aspire Biopharma (ASBP) Jumps on $100M Equity Line and Q3 Filing – What Matters on November 14, 2025

Aspire Biopharma (ASBP) Jumps on $100M Equity Line and Q3 Filing – What Matters on November 14, 2025

Aspire Biopharma Holdings (NASDAQ: ASBP) surged over 30% in pre-market trading Friday after announcing a new $100 million equity line of credit with Arena Business Solutions and releasing its Q3 2025 10-Q. Shares traded around $0.14, up from Thursday’s $0.11 close, with market cap near $5.3 million. The new deal replaces a prior ELOC signed in February.
14 November 2025
·
Aspire Biopharma (ASBP) Whipsaws on Heavy Volume Today as Investors Eye Reverse‑Split Authority and Nasdaq Compliance — Nov. 11, 2025

Aspire Biopharma (ASBP) Whipsaws on Heavy Volume Today as Investors Eye Reverse‑Split Authority and Nasdaq Compliance — Nov. 11, 2025

ASBP shares dropped roughly 20–25% mid-session Nov. 11, trading on heavy volume and swinging between $0.1189 and $0.2471. No new company news was released; the last updates were last week’s CPHI Frankfurt partnering recap and special meeting results. Nasdaq delisting risk remains after Aspire requested a hearing to contest compliance failures.
11 November 2025
·

Stock Market Today

  • Canadian National Railway (TSX:CNR) Near Fair Value After Recent Price Rise
    April 30, 2026, 12:19 AM EDT. Canadian National Railway's (TSX:CNR) share price has climbed 4.8% in the past month and 13.7% over the last year. The stock trades around CA$147.91, near its estimated intrinsic value of CA$150.02 from a discounted cash flow (DCF) analysis, suggesting it is fairly valued. Canadian National, a key North American freight infrastructure player, is supported by a robust capital investment program and stable cash flow projections through 2029 and beyond. Despite this, its 13.7% return trails some peers, reflecting ongoing market concerns about rail efficiency, regulation, and cross-border trade impacts. Investors should monitor updates as shifts in factors influencing long-term cash generation could affect valuation.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 30.04.2026

30 April 2026
OCBC will pay a total dividend of S$0.58 per share in May, including a S$0.16 special dividend. UOB declared a final dividend of S$0.71 per share despite lower net interest income. ST Engineering reported higher revenue and profit, with a S$0.23 per share dividend. Jardine Matheson raised its annual dividend 4% to US$2.35 per share, payable mid-May.
Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Go toTop